Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$79.67 USD
-0.13 (-0.16%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $79.69 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.67 USD
-0.13 (-0.16%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $79.69 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth B Momentum B VGM
Zacks News
BioMarin Initiates Gene Therapy Study for Phenylketonuria
by Zacks Equity Research
BioMarin (BMRN), a leader in the phenylketonuria segment, initiates development of its first gene therapy for treating the rare genetic enzyme deficiency disorder.
Dr. Reddy's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Dr. Reddy's Laboratories.
Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers
by Zacks Equity Research
Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.
Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips
by Zacks Equity Research
Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.
Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes
by Zacks Equity Research
Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.
FUJIFILM (FUJIY) Q1 Earnings Top Estimates, Revenues Drop Y/Y
by Zacks Equity Research
FUJIFILM's (FUJIY) fiscal first-quarter results reflect coronavirus impact on the top line and operating income.
Dr. Reddy's Laboratories' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Dr. Reddy's Laboratories.
Bausch (BHC) Q2 Earnings & Revenues Miss Estimates, Down Y/Y
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the second quarter and announces plans to spin off its eye care division.
Endo (ENDP) Q2 Earnings & Sales Beat as Coronavirus Impacts Ease
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the second quarter as COVID-19-related restrictions ease out.
Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues decline year over year in first-quarter fiscal 2021.
Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug
by Zacks Equity Research
Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.
The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY
by Zacks Equity Research
The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY
3 Stocks to Buy on New Drug Approvals by FDA
by Manaswita Ghosh Dutta
In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.
Dr. Reddy's Inks Deal With Gilead Sciences for Remdesivir
by Zacks Equity Research
Dr. Reddy Laboratories (RDY) inks a deal with Gilead to register, manufacture and sell the latter's Remdesivir ??? a potential treatment for COVID-19 ??? in 127 countries including India.
Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
Are You Looking for a Top Momentum Pick? Why Doctor Reddy's (RDY) is a Great Choice
by Zacks Equity Research
Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bull of the Day: Dr. Reddy's Laboratories (RDY)
by David Borun
Generic pharmaceuticals are among the most naturally defensive industries during uncertain times
Zacks.com featured highlights include: Rocky Brands, FTI Consulting, Stamps.com, Sprouts Farmers Market and Dr. Reddy???s Laboratories
by Zacks Equity Research
Zacks.com featured highlights include: Rocky Brands, FTI Consulting, Stamps.com, Sprouts Farmers Market and Dr. Reddy???s Laboratories
Beat Coronavirus Blues With These 5 Low-Beta Stocks
by Nilanjan Banerjee
A portfolio of low-beta stocks can protect your investments from the coronavirus-induced market volatility.
What Makes Doctor Reddy's (RDY) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Dr. Reddy's Laboratories Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Dr. Reddy's Laboratories
Amarin's Stock Plunges Following Unfavorable Patent Ruling
by Zacks Equity Research
Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.
Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings (excluding impairment charge) increase year over year in the third quarter of fiscal 2020.
New Strong Sell Stocks for January 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today